Clinical trial · Observational
Immune Suppression Of Infants Treated With Steroids
Immune Suppression of Infants Treated With Oral Corticosteroids for Infantile Hemangiomas: A Pilot Study
NCT00433940CI-TRIAL-00009123completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this study is to clarify the degree of immune suppression in infants requiring therapy and to create guidelines for evaluation and prevention of infection in infants on oral steroids for hemangiomas.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hemangioma | Hemangioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Prednisolone | Drug | Prednisolone | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Infantile Hemangioma Patients
- description
- Infants with infantile hemangioma being treated clinically with oral prednisolone sodium phosphate suspensions.
- interventionNames
- Drug: Prednisolone
Primary outcomes (1)
- measure
- Lymphocyte Subtest of Complete Blood Count Analysis (Primary Immunodeficiency)
- timeFrame
- 2 years
- description
- Measurement of absolute lymphocyte count and % lymphocyte found during a Complete Blood Count analysis.
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 6 Months
Show eligibility criteria text
Inclusion Criteria: * Infants \< 6 months of age with infantile hemangiomas requiring treatment with oral corticosteroids * Infant must be enrolled prior to initiation of steroid therapy Exclusion Criteria: * Infants \> 6 months of age * Infants already receiving oral corticosteroid treatment prior to the start of this study * Infants with know immunodeficiencies * Infants receiving other oral medications for the treatment of hemangiomas
References
Publications (0)
Data not yet available
No reference posted for this study.